View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Comment
April 22, 2020

Governments can avoid potential cancer drug shortages amid Covid-19 pandemic

By GlobalData Healthcare

As the Covid-19 pandemic escalates, the spread of the infection is putting increasing pressure on healthcare systems worldwide. While valuable medical resources are being diverted for management of the Covid-19 pandemic, there is a plausible concern that treatment of cancer patients could become overlooked or delayed, leading to deteriorating prognoses for this vulnerable population. The Covid-19 pandemic has already caused disruptions in global drug supply chains, and as the situation deepens, cancer drug shortages can arise as a result of these disruptions. Potential shortages of generic chemotherapies, in particular, could also lead to an increase in counterfeit cancer drugs, which would put the health and wellbeing of patients and the integrity of the healthcare systems into jeopardy. During these unprecedented times, it is important to ask what actions or initiatives could mitigate potential drug shortages and their impact on the treatment of cancer patients.

Free Report
img

Navigate your business through the ‘new normal’

COVID-19 continues to dominate headlines the world over. It has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities.  Faced with an explosion of conflicting information on how to plan and implement successful recovery strategies, decision-makers are in dire need of a single, reliable source of intelligence.   GlobalData’s COVID-19 Executive Briefing gives you access to unparalleled data and insights to successfully navigate the uncertain road to recovery across the world’s largest industries. Understand every aspect of this disruptive theme by delving into: 
  •  COVID-19 infection update, with statistics on the spread, testing by country, as well as the latest data on vaccines and therapeutic developments 
  • Economic impact overview, covering stock market indices, GDP, unemployment rates, policy responses & GlobalData’s economic recovery scorecards 
  • Sector developments, with access to sector insight summaries, cross-sector indices and the leaders and laggards in each industry vertical 
Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today. 
by GlobalData
Enter your details here to receive your free Report.

During the Covid-19 pandemic, both European and American health authorities have acknowledged disruptions in medical product supply chains and potential shortages of important drugs. While pharmaceutical production in China, the largest supplier of active pharmaceutical ingredients, will slowly resume, the manufacturing and distribution of critical cancer therapies could experience further disruptions.

Domestic manufacturers of generic chemotherapies represent an important part of the supply chain and are diversely affected by the ongoing pandemic. As countries are announcing their planned healthcare budgets for the management of Covid-19, the impact of unforeseen expenditure on other areas in the healthcare systems, such as funds for cancer therapies, will be an important development to monitor. While the manufacturers of generic chemotherapies are already under pressure due to low prices and difficult procurement processes dictated by governments, the Covid-19 pandemic could force some of these manufacturers to redirect their operations for the time being—or permanently.

With the potential shortages of cancer drugs, counterfeits could become a serious issue in both developed and developing countries. Regardless, drug shortages could push healthcare professionals to use less effective and more expensive alternatives to certain cancer therapies that form the backbone of treatment in various indications, which could lead to increased recurrences and climbing costs.

For many countries, potential shortages of cancer drugs during the outbreak of Covid-19 pandemic is an issue to be carefully managed. As a reaction, governments could be more inclined to stockpile or limit exportation of critical cancer drugs when there are shortages; however, while there are no serious cancer drug shortages yet during this pandemic, governments could also explore long-term solutions to implement. In 2019, the widespread shortages of vincristine, critical chemotherapy that is used in the treatment of acute lymphoblastic leukaemia, the most common cancer in children, led to the issuing of the Mitigating Emergency Drug Shortages (MEDS) Act in the US, which incentivised Teva Pharmaceuticals to reinitiate their manufacturing of vincristine. Similarly, preemptive government planning, raising manufacturing incentives, and relaxing drug procurement processes could be valuable initiatives during the pandemic to prevent shortages of cancer drugs. Other initiatives could also include forming National Essential Cancer Medicines Lists, and implementing communications across governments and industries to support the integrity of global medical supply chains. Lastly, the challenges due to the Covid-19 pandemic could create the opportunity to implement innovative technologies such as blockchain on a wider scale into the pharmaceutical supply chains, which would offer partial solutions for problems of distribution during the pandemic, and would help tackle the threat of increasing counterfeits of cancer therapies.

Related Companies

Free Report
img

Navigate your business through the ‘new normal’

COVID-19 continues to dominate headlines the world over. It has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities.  Faced with an explosion of conflicting information on how to plan and implement successful recovery strategies, decision-makers are in dire need of a single, reliable source of intelligence.   GlobalData’s COVID-19 Executive Briefing gives you access to unparalleled data and insights to successfully navigate the uncertain road to recovery across the world’s largest industries. Understand every aspect of this disruptive theme by delving into: 
  •  COVID-19 infection update, with statistics on the spread, testing by country, as well as the latest data on vaccines and therapeutic developments 
  • Economic impact overview, covering stock market indices, GDP, unemployment rates, policy responses & GlobalData’s economic recovery scorecards 
  • Sector developments, with access to sector insight summaries, cross-sector indices and the leaders and laggards in each industry vertical 
Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today. 
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU